Harmonization across programmed death ligand 1 (PD‐L1) assays for lung cancer by immunohistochemistry using noncontact alternating current electric field mixing

BACKGROUND: Immune checkpoint inhibitors (ICIs) are a promising advance in the treatment of patients with lung cancer. However, each ICI has been tested with an independently designed companion diagnostic assay that is based on a unique antibody. Consequently, the different trial‐validated programme...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuo, Tsubasa, Imai, Kazuhiro, Nanjo, Hiroshi, Takashima, Shinogu, Hiroshima, Yuko, Atari, Maiko, Kuriyama, Shoji, Ishii, Yoshiaki, Wakamatsu, Yuki, Sato, Yusuke, Motoyama, Satoru, Matsumura, Yuki, Suzuki, Hiroyuki, Nomura, Kyoko, Minamiya, Yoshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046066/
https://www.ncbi.nlm.nih.gov/pubmed/33650770
http://dx.doi.org/10.1111/1759-7714.13893

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046066/
https://www.ncbi.nlm.nih.gov/pubmed/33650770
http://dx.doi.org/10.1111/1759-7714.13893

Ejemplares similares